RCT of treatments for pyoderma gangrenosum: time to get involved

STOP-GAP Trial Management Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Pyoderma gangrenosum (PG) is a rare, painful ulcerating skin condition that is often associated with underlying systemic disease such as inflammatory bowel disease, rheumatoid arthritis and haematological malignancies. There has been little research done into treatments for the disease. Aims: The STOP GAP trial will be the first trial to investigate the two most commonly used treatments for PG. The study aims to test the hypothesis that ciclosporin (Neoral®) is more effective than systemic prednisolone for the treatment of PG. One hundred and forty patients will be recruited by April 2012. Methods: Patients with a clinical diagnosis of PG are being recruited from around 50 dermatology departments in secondary care trusts in the UK. They are being randomised to either prednisolone (0.75 mg/kg/day) or ciclosporin (4 mg/kg/day). For cases where topical therapy is indicated, patients are being entered into a parallel observational study. Results: The study is ongoing and results should be published by August 2013. Conclusions: The STOP GAP trial is now the largest randomised controlled trial (RCT) ever conducted in PG and will provide clinicians with an evidence base for the treatment of this debilitating condition for the first time.
Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalWounds UK
Volume6
Issue number4
Publication statusPublished - 8 Nov 2010

Fingerprint

Pyoderma Gangrenosum
Randomized Controlled Trials
Cyclosporine
Prednisolone
Therapeutics
Secondary Care
Hematologic Neoplasms
Dermatology
Inflammatory Bowel Diseases
Observational Studies
Rheumatoid Arthritis
Skin
Research

Cite this

STOP-GAP Trial Management Group (2010). RCT of treatments for pyoderma gangrenosum: time to get involved. Wounds UK, 6(4), 27-32.

RCT of treatments for pyoderma gangrenosum : time to get involved. / STOP-GAP Trial Management Group.

In: Wounds UK, Vol. 6, No. 4, 08.11.2010, p. 27-32.

Research output: Contribution to journalArticle

STOP-GAP Trial Management Group 2010, 'RCT of treatments for pyoderma gangrenosum: time to get involved', Wounds UK, vol. 6, no. 4, pp. 27-32.
STOP-GAP Trial Management Group. RCT of treatments for pyoderma gangrenosum: time to get involved. Wounds UK. 2010 Nov 8;6(4):27-32.
STOP-GAP Trial Management Group. / RCT of treatments for pyoderma gangrenosum : time to get involved. In: Wounds UK. 2010 ; Vol. 6, No. 4. pp. 27-32.
@article{7ddbd29feb5b440b9c66f70bb1c39aef,
title = "RCT of treatments for pyoderma gangrenosum: time to get involved",
abstract = "Background: Pyoderma gangrenosum (PG) is a rare, painful ulcerating skin condition that is often associated with underlying systemic disease such as inflammatory bowel disease, rheumatoid arthritis and haematological malignancies. There has been little research done into treatments for the disease. Aims: The STOP GAP trial will be the first trial to investigate the two most commonly used treatments for PG. The study aims to test the hypothesis that ciclosporin (Neoral{\circledR}) is more effective than systemic prednisolone for the treatment of PG. One hundred and forty patients will be recruited by April 2012. Methods: Patients with a clinical diagnosis of PG are being recruited from around 50 dermatology departments in secondary care trusts in the UK. They are being randomised to either prednisolone (0.75 mg/kg/day) or ciclosporin (4 mg/kg/day). For cases where topical therapy is indicated, patients are being entered into a parallel observational study. Results: The study is ongoing and results should be published by August 2013. Conclusions: The STOP GAP trial is now the largest randomised controlled trial (RCT) ever conducted in PG and will provide clinicians with an evidence base for the treatment of this debilitating condition for the first time.",
author = "Anthony Ormerod and {STOP-GAP Trial Management Group}",
year = "2010",
month = "11",
day = "8",
language = "English",
volume = "6",
pages = "27--32",
journal = "Wounds UK",
issn = "1746-6814",
publisher = "Wounds UK",
number = "4",

}

TY - JOUR

T1 - RCT of treatments for pyoderma gangrenosum

T2 - time to get involved

AU - Ormerod, Anthony

AU - STOP-GAP Trial Management Group

PY - 2010/11/8

Y1 - 2010/11/8

N2 - Background: Pyoderma gangrenosum (PG) is a rare, painful ulcerating skin condition that is often associated with underlying systemic disease such as inflammatory bowel disease, rheumatoid arthritis and haematological malignancies. There has been little research done into treatments for the disease. Aims: The STOP GAP trial will be the first trial to investigate the two most commonly used treatments for PG. The study aims to test the hypothesis that ciclosporin (Neoral®) is more effective than systemic prednisolone for the treatment of PG. One hundred and forty patients will be recruited by April 2012. Methods: Patients with a clinical diagnosis of PG are being recruited from around 50 dermatology departments in secondary care trusts in the UK. They are being randomised to either prednisolone (0.75 mg/kg/day) or ciclosporin (4 mg/kg/day). For cases where topical therapy is indicated, patients are being entered into a parallel observational study. Results: The study is ongoing and results should be published by August 2013. Conclusions: The STOP GAP trial is now the largest randomised controlled trial (RCT) ever conducted in PG and will provide clinicians with an evidence base for the treatment of this debilitating condition for the first time.

AB - Background: Pyoderma gangrenosum (PG) is a rare, painful ulcerating skin condition that is often associated with underlying systemic disease such as inflammatory bowel disease, rheumatoid arthritis and haematological malignancies. There has been little research done into treatments for the disease. Aims: The STOP GAP trial will be the first trial to investigate the two most commonly used treatments for PG. The study aims to test the hypothesis that ciclosporin (Neoral®) is more effective than systemic prednisolone for the treatment of PG. One hundred and forty patients will be recruited by April 2012. Methods: Patients with a clinical diagnosis of PG are being recruited from around 50 dermatology departments in secondary care trusts in the UK. They are being randomised to either prednisolone (0.75 mg/kg/day) or ciclosporin (4 mg/kg/day). For cases where topical therapy is indicated, patients are being entered into a parallel observational study. Results: The study is ongoing and results should be published by August 2013. Conclusions: The STOP GAP trial is now the largest randomised controlled trial (RCT) ever conducted in PG and will provide clinicians with an evidence base for the treatment of this debilitating condition for the first time.

M3 - Article

VL - 6

SP - 27

EP - 32

JO - Wounds UK

JF - Wounds UK

SN - 1746-6814

IS - 4

ER -